Literature DB >> 9753266

Effects of cyclooxygenase-2 selective and nitric oxide-releasing nonsteroidal antiinflammatory drugs on mucosal ulcerogenic and healing responses of the stomach.

H Ukawa1, H Yamakuni, S Kato, K Takeuchi.   

Abstract

Effects of selective cyclooxygenase-2 (COX-2) inhibitors (NS-398) and nitric oxide (NO) -releasing aspirin (NO-ASA) on gastric ulcerogenic and healing responses were examined in comparison with nonselective COX inhibitors such as indomethacin and aspirin (ASA). Hypothermic stress (28-30 degrees C, 4 hr) induced gastric lesions in anesthetized rats with an increase of acid secretion. The lesions induced by hypothermic stress were markedly worsened by subcutaneous administration of both indomethacin and ASA but were not affected by either NS-398 or NO-ASA, although the increased acid secretion during hypothermia was not affected by any of the drugs. On the other hand, the healing of gastric ulcers induced in mice by thermal cauterization (70 degrees C, 15 sec) was significantly delayed by daily subcutaneous administration of indomethacin and ASA as well as NS-398, but not by NO-ASA. COX-2 mRNA was not detected in the intact mucosa but was positively expressed in the ulcerated mucosa, most potently on day 3 after ulceration. Prostaglandin contents in the intact mouse stomach were reduced by indomethacin, ASA, and NO-ASA, while the increased prostaglandin generation in the ulcerated mucosa was inhibited by all drugs including NS-398. After subcutaneous administration of NO-ASA to pylorus-ligated rats and mice, high amounts of NOx were detected in both the gastric contents and serum. In addition, both NS-398 and NO-ASA showed an equipotent antiinflammatory effect against carrageenan-induced paw edema in rats as compared with indomethacin and ASA. These results suggest that both indomethacin and ASA not only increased the mucosal ulcerogenic response to stress but impaired the healing response of gastric ulcers as well. The former action was due to inhibition of COX-1, while the latter effect was accounted for by inhibition of COX-2 and was mimicked by the COX-2-selective inhibitor NS-398. NO-ASA, although it inhibited both COX-1 and COX-2 activity, had no deleterious effects on gastric ulcerogenic and healing responses.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9753266     DOI: 10.1023/a:1018846912032

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  33 in total

1.  Regulation of gastric mucosal integrity by endogenous nitric oxide: interactions with prostanoids and sensory neuropeptides in the rat.

Authors:  B J Whittle; J Lopez-Belmonte; S Moncada
Journal:  Br J Pharmacol       Date:  1990-03       Impact factor: 8.739

2.  Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative.

Authors:  J L Wallace; W McKnight; P Del Soldato; A R Baydoun; G Cirino
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

3.  A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in rats.

Authors:  S N Elliott; W McKnight; G Cirino; J L Wallace
Journal:  Gastroenterology       Date:  1995-08       Impact factor: 22.682

4.  NS-398, a novel non-steroidal anti-inflammatory drug with potent analgesic and antipyretic effects, which causes minimal stomach lesions.

Authors:  N Futaki; K Yoshikawa; Y Hamasaka; I Arai; S Higuchi; H Iizuka; S Otomo
Journal:  Gen Pharmacol       Date:  1993-01

5.  Effects of anti-ulcer agents on thermal-cortisone-induced ulcers in rats.

Authors:  N Inatomi; Y Ishihara; S Okabe
Journal:  Jpn J Pharmacol       Date:  1979-06

6.  Selective inhibition of NS-398 on prostanoid production in inflamed tissue in rat carrageenan-air-pouch inflammation.

Authors:  N Futaki; I Arai; Y Hamasaka; S Takahashi; S Higuchi; S Otomo
Journal:  J Pharm Pharmacol       Date:  1993-08       Impact factor: 3.765

7.  Prostaglandin biosynthesis by gastric mucosa. I. Studies in rat.

Authors:  J L Wallace; D R McCready; B C Chin; N S Track; M M Cohen
Journal:  Clin Biochem       Date:  1984-06       Impact factor: 3.281

8.  Selective inhibition of inducible cyclooxygenase 2 in vivo is antiinflammatory and nonulcerogenic.

Authors:  J L Masferrer; B S Zweifel; P T Manning; S D Hauser; K M Leahy; W G Smith; P C Isakson; K Seibert
Journal:  Proc Natl Acad Sci U S A       Date:  1994-04-12       Impact factor: 11.205

9.  NS-398, a new anti-inflammatory agent, selectively inhibits prostaglandin G/H synthase/cyclooxygenase (COX-2) activity in vitro.

Authors:  N Futaki; S Takahashi; M Yokoyama; I Arai; S Higuchi; S Otomo
Journal:  Prostaglandins       Date:  1994-01

10.  Reduction of gastrointestinal injury in acute endotoxic shock by flurbiprofen nitroxybutylester.

Authors:  J L Wallace; G Cirino; G W McKnight; S N Elliott
Journal:  Eur J Pharmacol       Date:  1995-06-23       Impact factor: 4.432

View more
  27 in total

Review 1.  Risk of anastomotic leakage with use of NSAIDs after gastrointestinal surgery.

Authors:  Christian Fredrik Rushfeldt; Baldur Sveinbjørnsson; Kjetil Søreide; Barthold Vonen
Journal:  Int J Colorectal Dis       Date:  2011-08-11       Impact factor: 2.571

Review 2.  Current approaches to prevent NSAID-induced gastropathy--COX selectivity and beyond.

Authors:  Jan C Becker; Wolfram Domschke; Thorsten Pohle
Journal:  Br J Clin Pharmacol       Date:  2004-12       Impact factor: 4.335

3.  Preconditioning stress prevents cold restraint stress-induced gastric lesions in rats: roles of COX-1, COX-2, and PLA2.

Authors:  Akiko Tanaka; Ryo Hatazawa; Yuka Takahira; Nahoko Izumi; Ludmila Filaretova; Koji Takeuchi
Journal:  Dig Dis Sci       Date:  2007-01-17       Impact factor: 3.199

4.  Telomere length in non-neoplastic gastric mucosa and its relationship to H. pylori infection, degree of gastritis, and NSAID use.

Authors:  Tomomitsu Tahara; Tomoyuki Shibata; Tomohiko Kawamura; Takamitsu Ishizuka; Masaaki Okubo; Mitsuo Nagasaka; Yoshihito Nakagawa; Tomiyasu Arisawa; Naoki Ohmiya; Ichiro Hirata
Journal:  Clin Exp Med       Date:  2015-01-07       Impact factor: 3.984

5.  Effect of COX-2 inhibitor lumiracoxib and the TNF-α antagonist etanercept on TNBS-induced colitis in Wistar rats.

Authors:  Ana Paula Ribeiro Paiotti; Daniel Araki Ribeiro; Roseane Mendes Silva; Patrícia Marchi; Celina Tizuko Fujiyama Oshima; Ricardo Artigiani Neto; Sender Jankiel Miszputen; Marcello Franco
Journal:  J Mol Histol       Date:  2012-03-20       Impact factor: 2.611

Review 6.  Prophylaxis and treatment of NSAID-induced gastroduodenal disorders.

Authors:  R La Corte; M Caselli; G Castellino; G Bajocchi; F Trotta
Journal:  Drug Saf       Date:  1999-06       Impact factor: 5.606

Review 7.  Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs.

Authors:  J E Keeble; P K Moore
Journal:  Br J Pharmacol       Date:  2002-10       Impact factor: 8.739

8.  Pharmacokinetic and pharmacodynamic study of NO-donating aspirin in F344 rats.

Authors:  Chinthalapally V Rao; Stancy Joseph; Li Gao; Jagan M R Patlolla; Chang-In Choi; Levy Kopelovich; Vernon E Steele; Basil Rigas
Journal:  Int J Oncol       Date:  2008-10       Impact factor: 5.650

9.  Low-dose aspirin reduces gastro-protective properties of COX-2 selective inhibitors.

Authors:  João Soares
Journal:  Clin Drug Investig       Date:  2009       Impact factor: 2.859

10.  Effect of COX-2 inhibitor after TNBS-induced colitis in Wistar rats.

Authors:  Ana Paula Ribeiro Paiotti; Sender Jankiel Miszputen; Celina Tizuko Fujiyama Oshima; Henrique de Oliveira Costa; Daniel Araki Ribeiro; Marcello Franco
Journal:  J Mol Histol       Date:  2009-11-22       Impact factor: 2.611

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.